Aim of the study was to test, in a cooperative and prospective trial, the effectiveness and feasibility of a chemo-radio-therapy program in stage III non small cell lung cancer (NSCLC).
Methods
The schedule consisted in carboplatin (CBDCA) 150 mg/m2/iv on days 1, 3, 5 and vindesine VDS 2.5 mg/m2/iv on days 1, 8, 15, 22 every 4 weeks for 2 cycles followed by radiotherapy 60 Gy with CBDCA 50 mg/m2 weekly as radioenhancer. The same schedule was proposed as neoadjuvant treatment in 10/47 patients (stage III A) and as exclusive treatment in 37/47 (stage III B) admitted patients.
Results
In the neoadjuvant subgroup partial remission was obtained in 5/10 patients, and 3 of them underwent surgery with consequent CR. In the stage III B subgroup, 2 complete remissions were obtained (survival 14 and 9+ months). Toxicity was mild.
Conclusions
Our results confirm the feasibility of the schedule in stage III NSCLC.
BeggA.C., Van Der KolkP.J., EmondtJ., BartelinkH.: Radiosensitization in vitro by cis-diammine (1,1 cyclobutanedicarboxylato-platinum (II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum (II) (JM40).Radiother. Oncology,9: 157–165, 1987.
2.
BrahmeA.: Accuracy requirements and quality assurance of external beam therapy with photos and electron.Acta Oncologica: Suppl., 1, 1–76, 1988.
3.
BunnP.A.: The expanding role of cisplatin in the treatment of non-small cell lung cancer.Semin. Oncol.,16: 10–21, 1989.
4.
CrinóL., TonatoM., DarvishS., MeacciM.L., CorgnaE., Di CostanzoF., BuzziF., FornariG., SantiE., BallatoriE.: A randomized trial of 3 cisplatin-containing regimens in advanced non-small cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group.Cancer Chemother. Pharmacol.,26: 52–56, 1990.
DoupleE.B., RichmondR.C., O'HaraJ.A., CoughlinC.T.: Carboplatin as a potentiator of radiation therapy.Cancer Treat. Rev.,12 Suppl. A: 111–124, 1985.
7.
ElliotJ.A., AhmedzaiS., HoleD., DorwardA.J., StevensonR.D., KayeS.B., BonhamS.W., StackB.H., CaimanK.C.: Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study.Eur. J. Cancer Clin. Oncol.,20: 1025–1032, 1984.
8.
FerrazziE., ZagonelV., VinanteO., GalligoniE., PappagalloG.L., CarteiG., FiorentinoM.V.: Vindesine in the treatment of squamous cell carcinoma (WHO I), adenocarcinoma (WHO III) and large cell carcinoma (WHO IV) of the lung.Tumori,68: 531–535, 1982.
9.
GreenM.R.: Carboplatin in non-small cell lung cancer: The Cancer and Leukemia Group B Experience. In: Carboplatin (JM-8). Current Perspectives and Future Directions, Bunn P.A. e coll. (Eds.), pp. 301–306, W.B. Saunders, Philadelphia, 1990.
10.
IsraelL., BreauJ.L., ClavierJ., DepierreA., DavidP., LemarieE., TcherakianF., BàttestiJ.P.: Combination with continuous cisplatinum and bleomycin for squamous cell lung cancer in 196 patients. Ist. Conv. Soc. Europ. Pneumol. Knokke-Bruges, 1982 in Europe,J. Resp. Dis.,63: Abstr. 98, 1982.
11.
JacobsR.H., BritainJ.D.: Chemotherapy as an adjuvant to surgery and radiotherapy in stage III non-small cell lung cancer in: Lung Cancer: A Comprehensive Treatise.BritanJ.D., GolombH.M., LittleA.G., WeichselbaummR.R. (Eds.), pp. 221–232, Grune and Stratton, New York, 1988.
12.
KlasterskyJ.: Cisplatin plus etoposide versus carboplatin plus etoposide in the treatment of advanced non-small cell lung cancer: a preliminary report. In: Carboplatin (JM-8). Current Perspectives and Future Directions.BunnP.A. (Eds.), pp. 329–337, W.B. Saunders, Philadelphia, 1990.
13.
KlasterskyJ., SculierJ.P., BureauG., LibertP., RavezP., VandermotenG., ThirianxJ., LecomteJ., CordierR., DabouisG.: Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. Lung Cancer Working Party Belgium.J. Clin. Oncol.,7: 1087–1092, 1989.
14.
MitrouP.S., FischerH., SchneiderM.: Chemotherapy of inoperable non-small cell carcinoma of the lung with vindesine, cisplatinum and cyclophosphamide, a pilot study.Proc. Internat., Vinca Alkaloid Symposium-Frankfurt:405–409, November 1980.
15.
O'HaraJ.A., DoupleE.B., RichmondC.R.: Enhancement of radiation-induced cell kill by platinum complexes (carboplatin and iproplatin) in V19 and cells.Int. J. Radiat. Oncol. Biol. Phys.,12: 1419–1422, 1986.
16.
PairoleroP.C., TrastekV.F., PayneW.S.: Treatment of bronchogenic carcinoma with chest wall invasion.Surg. Clin. N. Am.,67: 959–964, 1987.
17.
ShermanD.M., NeptuneW., WeichselbaumR., OrderS.E., PiroA.J.: An aggressive approach to marginally resectable lung cancer.Cancer,41: 2040–2045, 1978.
18.
ShieldsT.W.: Preoperative radiation therapy in the treatment of bronchial carcinoma.Cancer,30: 1388–1394, 1972.
19.
SkarinA., JochelsonM., SheldoneT., MalcolmA., OliynykP., OverholtR.: Hunt M., Frei E. 3d: Neoadjuvant chemotherapy in marginally resectable stage III MO non-small cell lung cancer: long-term follow-up in 41 patients.J. Surg. Oncol.,40: 266–274, 1989.
20.
SpainR.C., JostJ., KircherT., SpeerJ.F., AndersonP.N., ZinnC.J., KerseyD., SchillerJ.: Neoadjuvant mitomycin, cisplatin, and infusion vinblastine with reduced pulmonary toxicity in stage III non-small cell lung cancer in: Adjuvant Therapy of Cancer.SalmonS.E. (Ed.), pp. 165–177, Grune and Stratton, New York, 1987.
21.
SpainR., AndersonP., SpeerJ.: Improved survival with mitomycin-C, cisplatinum in stage III limited, initially inoperable, non-small cell lung cancer.Proc. IV World Conference on Lung Cancer, Toronto. P: 33, 1985.
22.
SteelG.G.: Terminology in the description of drug-radiation interaction.Int. J. Radiat. Oncol. Biol. Phys.,5: 1145–1150, 1979.
23.
StooplerM.B., KelsenD.P., GrallaR.J., CasperE.S., ChengE., GolbeyrS.: Vindesine (DVA), cis-dichloro-diammine platinum II (DDP), Cytoxan (CTX) and adriamycin (ADR) combination chemotherapy in non-small cell lung cancer (NSCLC).Proc. Asco,21: 457, 1980.
24.
SoresiE., ClericiM., GrilliR., BorghiniU., ZucaliR., LeoniM., BotturiM., VergariG., LuporiniG., ScocciaS.: A randomized clinical trial comparing radiation therapy v. radiation therapy plus cis-dichlorodiammine platinum (II) in the treatment of locally advanced non-small cell lung cancer.Semin. Oncol.,15: 20–25, 1988.
25.
TaylorS.G., TrybulaM., BonomiP.D., FaberL.P., LeeM.S., ReddyS., MaffeyS.C., MathisenD.J., JensikR.J., KittleC.F.: Simultaneous cisplatin and fluorouracil infusion and radiation followed by surgical resection in regionally localized stage III NSCLC.Ann. Thorac. Surg.,43: 87–91, 1987.
26.
TouraniJ.M., TinsitF., DelaisementC., BalzonJ.C., CaubarrereI., DarseJ., GeraadsA., LebasF.X., AndrieuJ.M.: Two cycles of cisplatin-vindesine and radiotherapy for localized non-small cell carcinoma of the lung (stage III).Cancer,65: 1472–1477, 1990.
27.
WarremJ.: Preoperative irradiation of cancer of the lung: final report of a therapeutic trial.Cancer,36: 914–925, 1975.
28.
WeidenP., PiantadosiS.: Preoperative chemotherapy in stage III non-small cell lung cancer: phase II study of the Lung Study Group.Proc. Asco,7: 761, 1988.
